Catheter Precision, Inc. Receives Notice of First Patent Allowance in the US for LockeT Product Line
Catheter Precision Press Release
Fort Mill, S.C., April 14, 2025 -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced that it has received a notice of allowance from the US Patent Office of its first patent in the US for its LockeT product, filed in December 2022, for its design of a surgical closure device for orthoscopic entry wounds.
David Jenkins, CEO of Catheter Precision, commented, “This first US patent for LockeT joins our other issued international LockeT patents that have now been issued in China, Europe, and the United Kingdom. Intellectual property protection within this large market is quite meaningful to us as we begin discussions for distribution in China and also Europe. We expect to receive the CE mark for LockeT in this quarter which clears the way to begin revenue creation in Europe. In markets outside of the United States, hospitals are also looking for new products that provide great outcomes while reducing cost per procedure. Our LockeT fits these parameters well. In the US, we began our roll out late last year, and we are quite pleased with the reception so far.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in wound closure after percutaneous venous punctures. LockeT is a Class 1 device registered with the FDA.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
